Top ▲

Chronic idiopathic urticaria

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1232
Name:Chronic idiopathic urticaria
Associated with:0 target
2 immuno-relevant ligands
Description
A condition characterised by frequent and recurrent wheals and itching with no known cause.

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Chronic idiopathic urticaria

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
omalizumab
Immuno Disease Comments: An anti-IgE therapy approved to treat antihistamine-resistant chronic idiopathic urticaria .
Clinical Use: Used to treat moderate to severe IgE-mediated (i.e. allergy triggered) persistent asthma (US) or severe asthma (EU) [4], in adults and children over 12 years old, inadequately controlled by inhaled corticosteroid treatment. In 2014 the US FDA approved use of this drug for the treatment of chronic idiopathic urticaria (CIU, a.k.a. chronic spontaneous urticaria) which is unresponsive to treatment with anti-histamine H1 receptor drugs.
In July 2016, the FDA expanded asthma approval to include children six to 11 years of age, as indicated previously for those 12 years-adult. Omalizumab has also been evaluated for efficacy to provide protection from food-driven allergic reactions or to augment oral desensitisation protocols [1-3,5]. In February 2024, it became the first FDA approved drug to reduce the risk of IgE-mediated allergic reactions (including anaphylaxis) to >1 food allergen. | View clinical data
loratadine
Immuno Disease Comments: Antihistamine approved for CIU.
Clinical Use: Loratidine is used to relieve the symptoms of allergic rhinitis and chronic idiopathic urticaria. | View clinical data

References

Show »

1. Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, Umetsu DT, Rachid R, Chatila TA. (2018) Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function. Clin Exp Allergy, 48 (7): 825-836. [PMID:29700872]

2. Asero R. (2017) Disappearance of severe oral allergy syndrome following omalizumab treatment. Eur Ann Allergy Clin Immunol, 49 (3): 143-144. [PMID:28497679]

3. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT. (2012) Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol, 5 (3): 267-76. [PMID:22318492]

4. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol, 108 (2): 184-90. [PMID:11496232]

5. Lieberman JA, Chehade M. (2013) Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep, 13 (1): 78-84. [PMID:23065311]